Bupropion
Prescription antidepressant for depression and quitting smoking; causes sexual problems less often than many other antidepressants.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is Bupropion?
Bupropion is a prescription antidepressant for depression, seasonal depression and to help people quit smoking. Compared with the common serotonin reuptake inhibitor antidepressants, it less often causes sexual problems and does not make people sleepy.
In the brain it raises the levels of the messenger substances noradrenaline and dopamine, and it blocks the sites where nicotine acts, which helps with quitting. Studies show it works about as well as serotonin reuptake inhibitors in depression, and among people trying to quit smoking nearly twice as many stayed smoke-free for a year with it as with placebo. Insomnia and dry mouth are very common. The official prescribing information warns that suicidal thoughts and behavior may increase at the start of treatment in children, teenagers and young adults. It can also cause seizures, so it must not be used in epilepsy or eating disorders, and together with MAO inhibitors it can cause a dangerous rise in blood pressure.
ATC code
N06AX12
Prescription
Prescription only (Rx)
Mechanism
Norepinephrine and dopamine reuptake inhibitor; nicotinic receptor blocker
Half-life
~21 h (hydroxybupropion metabolite 20-37 h)
Onset
1-2 weeks (motivation, focus), 4-6 weeks (full AD effect)
Anecdotal reports describe Bupropion as a versatile NDRI antidepressant with notable motivation- and drive-boosting effects via dopamine and norepinephrine enhancement. Community accounts note strong efficacy for low-motivation depression presentations, including ADHD-overlap cases. Its low DAT affinity suggests it acts more as a dopaminergic modulator via VMAT-2 than a direct reuptake blocker. Nicotinic receptor antagonism underlies its FDA-approved smoking-cessation indication (Zyban); ongoing research examines utility in cocaine, methamphetamine, and impulsive-behavior disorders. Bupropion can be paradoxically activating or overstimulating, with a narrow therapeutic window. Mechanistic notes: nitric oxide donors and PDE-5 inhibitors (Sildenafil, Tadalafil) may blunt antidepressant efficacy; methylene blue appears to potentiate it. Caution: seizure threshold lowering – contraindicated in eating disorders and seizure history.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB . A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.. Arch Gen Psychiatry.
Weihs KL, Settle EC Jr, Batey SR et al. . Bupropion versus paroxetine for the treatment of major depressive disorder. J Clin Psychiatry. 2000;61(3):196-202..
Cipriani A, Furukawa TA, Salanti G et al. . Comparative efficacy and acceptability of 21 antidepressant drugs for major depressive disorder. Lancet. 2018;391(10128):1357-1366..
Niemegeers P, Dumont GJ, Patteet L, Neels H, Sabbe BG . Bupropion for the treatment of seasonal affective disorder.. Expert Opin Drug Metab Toxicol.
Greenway FL, Fujioka K, Plodkowski RA et al. . Effects of naltrexone-bupropion on weight loss (COR-I trial). Lancet. 2010;376(9741):595-605..
Davidson J. . Bupropion and seizure risk: a systematic review. J Clin Psychiatry. 1989;50(7):256-61..
Safarinejad MR . The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.. BJU Int.
Safety
Side effects, stop signs, contraindications
Side effects · 8
- BOXED WARNING: increased risk of suicidal thoughts and behavior in children, adolescents and young adults (<25 yrs) at treatment start or dose change; close monitoring required.
- Dose-dependent seizures: ~0.1% at standard dose (≤300 mg/day), ~0.4% at 450 mg/day, exponential above; the hallmark serious risk. Respect max dose (SR 400, XL 450 mg/day); do not crush tablets.
- Insomnia (15-20%), dry mouth (10-15%) and headache (~10%); to limit insomnia, take the last dose by early afternoon (around 5 pm).
- Agitation, anxiety, restlessness and tremor, especially in the first weeks; an activating, non-sedating profile with a narrow therapeutic window.
- Blood pressure elevation (dose-dependent NDRI effect); monitor BP at initiation, especially when combined with nicotine replacement or other sympathomimetics.
- Weight loss / reduced appetite (5-8%); weight-neutral or weight-reducing unlike SSRIs (often a benefit, but a concern in eating disorders).
- Neuropsychiatric events: may trigger mania/hypomania in bipolar patients (NDRI activation); rarely psychotic symptoms, hallucinations or paranoia, mainly at high doses.
- Hypersensitivity reactions: rash, urticaria, pruritus; rarely serum-sickness-like reaction or Stevens-Johnson syndrome; discontinue if rash persists or worsens.
Contraindications · 4
- Seizure disorder (epilepsy) history or known predisposition
- Eating disorders (bulimia, anorexia nervosa) – elevated seizure risk
- Acute alcohol or benzodiazepine withdrawal (seizure risk)
- Concurrent or within-14-days MAOi use (hypertensive crisis)
Related Pharmaceuticals
Same therapeutic category
Studies
Related research and clinical findings
A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.
Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB
Bupropion versus paroxetine for the treatment of major depressive disorder
Weihs KL, Settle EC Jr, Batey SR et al.
Comparative efficacy and acceptability of 21 antidepressant drugs for major depressive disorder
Cipriani A, Furukawa TA, Salanti G et al.
Bupropion for the treatment of seasonal affective disorder.
Niemegeers P, Dumont GJ, Patteet L, Neels H, Sabbe BG
Effects of naltrexone-bupropion on weight loss (COR-I trial)
Greenway FL, Fujioka K, Plodkowski RA et al.
Bupropion and seizure risk: a systematic review
Davidson J.
The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
Safarinejad MR
Telegram
Have a question about Bupropion?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.
